Metabolic News Weekly: November 5, 2024
Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs November 4, 2024 / GLP-1 Drugs / Novo Nordisk Partnership / Obesity Treatment Innovation / Diabetes / Drug Delivery / Cardiometabolic Disease Therapies Novo Nordisk and Ascendis Pharma are...